Monocentric retrospective cohort of 30,423 COVID-19 patients

Population and design: Monocentric cohort comparing COVID-19 patients
exposed or not exposed to the treatment hydroxychloroquine
(HCQ)+azithromycin (AZ) used as a standard of care in our center (Institut
Hospitalo-Universitaire (IHU) Méditerranée Infection, Marseille, France).
The inclusion period was from 2 March 2020 to 31 December 2021, with a
follow-up period of 6 weeks. Inclusion and exclusion criteria: Data
included were those of patients ≥ 18 years of age with PCR-proven COVID-19
disease regardless of symptoms (asymptomatic or symptomatic) and treated
in our centre, i.e. having had a medical examination by one of the doctors
in our centre (Institut Hospitalo-Universitaire (IHU) Méditerranée
Infection, Marseille, France) either as outpatients or as inpatients, i.e.
hospitalized on the day of the visit in our outpatient unit following
evaluation or directly transferred from another medical ward except
intensive care unit. The reasons for exclusion were an erroneous patient
identification (identity surveillance and duplicates), lack of available
medical data, lack of COVID-19 after checking the medical record
(including patients without COVID-19 consulting for a post-COVID-19
syndrome), expression of opposition to the use of their medical data for
research purposes (in accordance with European General Data Protection
Regulation), and data from patients hospitalized in our center after
intensive care. Data from COVID-19 outpatients left without medical advice
were excluded.